Analyzing Swedish Orphan Biovitrum (OTCMKTS:BIOVF) and Surrozen (NASDAQ:SRZN)

Surrozen (NASDAQ:SRZN – Get Free Report) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.

Volatility & Risk

Surrozen has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Earnings and Valuation

This table compares Surrozen and Swedish Orphan Biovitrum”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Surrozen $3.48 million 172.22 -$242.03 million ($43.21) -0.73
Swedish Orphan Biovitrum $2.89 billion 6.30 $48.85 million $2.01 25.40

Swedish Orphan Biovitrum has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Surrozen and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Surrozen -2,885.33% N/A -112.96%
Swedish Orphan Biovitrum 20.67% 17.92% 9.30%

Institutional and Insider Ownership

66.6% of Surrozen shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Surrozen and Swedish Orphan Biovitrum, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surrozen 1 1 5 0 2.57
Swedish Orphan Biovitrum 0 3 5 0 2.62

Surrozen currently has a consensus price target of $61.75, suggesting a potential upside of 96.37%. Given Surrozen’s higher probable upside, analysts clearly believe Surrozen is more favorable than Swedish Orphan Biovitrum.

Summary

Swedish Orphan Biovitrum beats Surrozen on 8 of the 13 factors compared between the two stocks.

About Surrozen

(Get Free Report)

Surrozen, Inc. is a biotechnology company developing antibody-based medicines designed to activate the Wnt signaling pathway, which plays a role in tissue growth and repair. The company uses its proprietary platform to develop therapies intended to stimulate regeneration in specific tissues while limiting effects elsewhere in the body. Surrozen’s research has included candidates aimed at liver disease and inflammatory bowel disease, including SZN-043 and SZN-1326. Its work focuses on advancing potential treatments through research and clinical development; the company’s products are investigational and are not approved medicines.

About Swedish Orphan Biovitrum

(Get Free Report)

Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.